The company's core product, "Yumenqing (Weijiekang)", is derived from the family formula passed down by its founder, Fang Fang. In 2000, based on this formula, the product was officially launched at the Guangzhou Beauty Expo. The market response was positive, the initial treatment effect of users was good, and the demand for the product continued to increase in the subsequent market. Facing the huge market demand, Fangfang invested funds in in-depth development, detailing the implementation steps in all aspects such as raw material supply, formula, and production process flow. A total of 3,800 experiments were conducted on mice and rats. The final results showed that the product had a significant stress response to multi-target gynecological viral inflammation within 24 hours, with adverse reactions below 6‰.

On March 3, 2004, the product was granted a patent for the built-in traction pill by the State Intellectual Property Office, with the patent number ZL03218613.4.

In 2005, the built-in traction pill was tested on 200 to 300 people in well-known tertiary hospitals such as Peking University People's Hospital and Beijing Obstetrics and Gynecology Hospital. It was unanimously recognized by experts and patients, and the clinical response was extremely good.

In December 2006, under the supervision and guidance of Mr. Yan Renying, the "Mother of Gynecology in China" (former president of Beijing Obstetrics and Gynecology Hospital), after being verified by 50 clinical patients, Mr. Yan happily inscribed "Weijiekang", expressing that Weijiekang cares for women's health and jointly creates a harmonious society.

In July 2007, Weijiekang collaborated with the Zaozhuang Family Planning Association to provide donation assistance to 50 impoverished mothers and promptly followed up on them. The assistance received a favorable response from the recipients and was recognized by the organizing unit.

In July 2019, technical service contracts were signed respectively with Beijing Yingkerui Drug Safety and Efficacy Research Co., Ltd. and Yingkerui (Tianjin) Innovative Pharmaceutical Research Co., LTD., discussing the efficacy tests and dosage form screening of Yumen Qing. In November 2019, the new dosage form was finalized. In December 2019, it was determined that the new dosage form, the old dosage form and the most effective drug recommended by a national authoritative medical institution - German imported Aibao Therapy - would be used for efficacy comparison tests. The test disease was chronic cervicitis. In April 2020, a summary report on the effects of different dosage forms of Yumenqing on a rat model of chronic cervicitis was released. The results were encouraging, indicating that Yumenqing was superior to German Aibao Therapy in both efficacy and adverse reactions.

Based on the family formula passed down by the founder, since 2000, the company has been exploring various sales methods in different markets, forming a multi-production and supply pattern that includes its own brands Weijiekang and Yumenqing, as well as OEM brands such as Jinshengdan, Fengbaoping, and Kangmeidan. At the same time, it also provides semi-finished products to other manufacturers, such as Zhengzhou Bokai Health Products Co., LTD. Over the past 20 years, the company has cumulatively produced more than 50 million built-in traction pills (granules) and more than 50 million bags of feminine wash antibacterial powder, with a total retail sales exceeding 3 billion yuan. The current manufacturer is Luoyang Guojitang Supply Chain Co., LTD., with the product production qualification being Weixiao Approval number. The general distributor is Luoyang Qianlele Fang Co., LTD.

It has been over 20 years since the product was first launched on the market. Over the past 20 years, it has gained a good reputation among users and accumulated a large number of user reports and medical records. The built-in traction pills (granules) and feminine wash antibacterial powder are designed to address various gynecological issues faced by women aged 20 to 60, and thereby further solve facial skin problems caused by gynecology.

For a long time, there have been no effective solutions for chronic cervicitis both at home and abroad. Worldwide, it has brought endless troubles to a large number of women aged 20 to 60. From the perspective of users, whether in urban or rural areas, whether in China or abroad, there is a huge market demand for built-in traction pills (granules) and feminine antibacterial powder.

From the perspective of the company's operation, the current sales mainly focus on entrusted processing, with the entrusting party mainly engaging in direct sales. The sales areas are mainly second -, third -, fourth -, and fifth-tier cities as well as rural areas. Due to the wide range of product categories offered by the client, the built-in traction pills (granules) and the antibacterial powder for women's washing are cross-sold with various health products, and the selling points are not very clear. The advantages of the product itself, which is powerful and has its own traffic, have not been fully exploited. Analysis shows that if there is a good model and appropriate resources from all parties, this single product should be able to bring in sales of 1 to 2 billion yuan a year.

Founder and CEO Fang Fang has nearly 40 years of working experience and has held positions at Shaanxi Hardware and Mineral Import & Export Corporation, Beijing Wantong Industrial Co., LTD., and Shanghai Jinpeng Futures Brokerage Co., LTD. Since May 2004, he has successively established Beijing Guojitang Biotechnology Co., LTD., Zhengzhou Guojitang Health Care Technology Co., LTD., Zhengzhou Guojitang Trading Co., LTD., Luoyang Guojitang Supply Chain Co., LTD., and Luoyang Qianlele Formula Co., LTD., serving as the chairman and general manager.